Vaccine Therapy in Treating Patients With Metastatic Melanoma
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.
| Condition | Intervention | Phase |
|---|---|---|
|
Melanoma (Skin) |
Biological: recombinant vaccinia-TRICOM vaccine |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma |
| Study Start Date: | August 2001 |
OBJECTIVES:
- Determine the maximum tolerated dose of recombinant vaccinia-TRICOM vaccine in patients with metastatic melanoma.
- Determine the clinical toxic effects of this vaccine in these patients.
- Determine the safety of this vaccine in these patients.
- Determine the clinical response of these patients to this vaccine.
- Determine evidence of host anti-melanoma immune reactivity in these patients after treatment with this vaccine.
OUTLINE: This is a dose-escalation study.
Patients receive recombinant vaccinia-TRICOM vaccine once every 4 weeks for a total of 3 vaccinations. Patients with stable or responding disease may receive an additional course of vaccinations.
Cohorts of 3-6 patients receive escalating doses of recombinant vaccinia-TRICOM vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
Quality of life is assessed at baseline, at each vaccine administration, and at study completion.
Patients are followed at 3 months.
PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study within 6-12 months.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Histologically confirmed metastatic non-resectable cutaneous, subcutaneous, or lymph node malignant melanoma
- Lesion(s) must be accessible to percutaneous injection
Measurable lesion(s)
- At least 1.0 cm
Previously treated brain metastases with no evidence of disease or edema on MRI or CT scan allowed
- At least 6 weeks since prior definitive therapy (surgery or radiotherapy)
- No untreated or edematous metastatic brain lesions or leptomeningeal disease
- No ascites or pleural effusions
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- ECOG 0-1
Life expectancy:
- More than 3 months
Hematopoietic:
- WBC at least 3,000/mm3
- Platelet count at least 100,000/mm3
- Absolute granulocyte count at least 3,000/mm3
- Hemoglobin at least 10 g/dL
Hepatic:
- Direct bilirubin no greater than 1.5 mg/dL
- Transaminases no greater than 2 times upper limit of normal (ULN)
- Alkaline phosphatase no greater than 2 times ULN
- No severe coagulation disorder with PT/PTT greater than 2 times normal (without anticoagulation medications)
- No hepatic insufficiency
- No alcoholic cirrhosis
Renal:
- Creatinine no greater than 2.0 mg/dL OR
- Creatinine clearance at least 60 mL/min
- No renal insufficiency
Cardiovascular:
- No congestive heart failure
- No serious cardiac arrhythmias
- No evidence of recent prior myocardial infarction on EKG
- No clinical coronary artery disease
Pulmonary:
- No chronic obstructive pulmonary disease
Immunologic:
- No prior eczema
- HIV negative
- No immunocompromising conditions, (e.g., active autoimmune disease, leukemia, lymphoma, skin diseases, or open wounds)
- No clinical or laboratory evidence of an underlying immunosuppressive disorder
- No active or chronic infections
- No significant allergy or hypersensitivity to eggs
Other:
- No active seizure disorders
- No other malignancy within the past 2 years except stage I cervical cancer or basal cell skin cancer, provided the tumor has been successfully treated and patient is currently disease free
- No evidence of bone marrow toxicity
- No other concurrent medical illness that would preclude study
- No other contraindications to vaccinia virus administration
- No encephalitis
- Must be able to avoid close contact with children under 3 years of age; pregnant women; individuals with prior or active eczema or other open skin conditions; or immunosuppressed individuals for 7-10 days after each vaccination
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Prior vaccinia immunization required (e.g., smallpox vaccination)
- More than 8 weeks since prior immunotherapy and recovered
- No prior therapy with live vaccinia virus vector
Chemotherapy:
- More than 4 weeks since prior chemotherapy and recovered
Endocrine therapy:
- At least 4 weeks since prior systemic corticosteroids
- No concurrent systemic corticosteroids
- No concurrent steroids
Radiotherapy:
- See Disease Characteristics
- More than 2 weeks since prior radiotherapy and recovered
Surgery:
- See Disease Characteristics
- More than 4 weeks since prior surgery for primary tumor or metastatic lesions and recovered
Other:
- No concurrent immunosuppressive drugs
Contacts and Locations| United States, New York | |
| Herbert Irving Comprehensive Cancer Center at Columbia University | |
| New York, New York, United States, 10032 | |
| Study Chair: | Howard L. Kaufman, MD | Herbert Irving Comprehensive Cancer Center |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00022568 History of Changes |
| Other Study ID Numbers: | CDR0000068831, CPMC-IRB-14387, AECM-01-003, NCI-3353 |
| Study First Received: | August 10, 2001 |
| Last Updated: | February 6, 2009 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
stage IV melanoma recurrent melanoma |
Additional relevant MeSH terms:
|
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas |
ClinicalTrials.gov processed this record on May 16, 2013